AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27684818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT
Number of subjects: 60
Study 24439687 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosomatic day hospital treatment
Number of subjects: 0
Study 24439687 — intervention group
Group type: COMPARATOR
Intervention: Waiting time before admission (control condition)
Number of subjects: 0
Study 22498844 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensed protocol (educational brochure)
Number of subjects: 280
Study 22498844 — intervention group
Group type: COMPARATOR
Intervention: Extended protocol (in-person education session)
Number of subjects: 280
Study 19197129 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and propofol administered by TCI (blood concentration: 3-5 microg/L for remifentanil and 3-5 mg/L for propofol)
Number of subjects: 80
Study 19197129 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl and propofol administered by TCI (fentanyl infusion: 2-3 microg/(kg.h), same propofol concentration as Group R)
Number of subjects: 80
Study 17496586 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of completely autologous platelet gel
Number of subjects: 111
Study 17496586 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 111
Study 15216550 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine clinical diagnosis plus genetic testing (mutation searching in probands and direct gene testing in relatives)
Number of subjects: 341
Study 15216550 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical diagnosis
Number of subjects: 341
Study 11913682 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative application of estriol ointment (n = 14)
Number of subjects: 26
Study 11913682 — intervention group
Group type: COMPARATOR
Intervention: Postoperative application of dexpanthenol ointment (n = 12)
Number of subjects: 26
Study 9702623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 60
Study 9702623 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 60
Study 7796767 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Vi polysaccharide vaccine (Typhim Vi), single intramuscular injection.
Number of subjects: 435
Study 2142081 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg tid
Number of subjects: 90
Study 2142081 — intervention group
Group type: COMPARATOR
Intervention: Frusemide 40 mg daily
Number of subjects: 90
Study 2142081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 624819 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (Colestid)
Number of subjects: 40
Study 624819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31344339 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine tampon
Number of subjects: 54
Study 31344339 — intervention group
Group type: COMPARATOR
Intervention: Control (wound closure and rinsing with Monoject syringe)
Number of subjects: 54
Study 28034579 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based self-regulation intervention (6 sessions)
Number of subjects: 422
Study 25682378 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational video about IBIs
Number of subjects: 128
Study 25682378 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 128
Study 24065421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation and exercise (CRE)
Number of subjects: 44
Study 24065421 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 44
Study 21249382 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly fit adolescent football players (peak VO(2) 43.5 ± 3.4 ml kg(‐1) min(‐1))
Number of subjects: 22
Study 21249382 — intervention group
Group type: COMPARATOR
Intervention: Untrained girls (peak VO(2) 36.0 ± 5.1 ml kg(‐1) min(‐1))
Number of subjects: 22
Study 21249382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during acute bout of exercise
Number of subjects: 22
Study 19963157 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL apple cider vinegar, 40 mL water
Number of subjects: 5
Study 19963157 — intervention group
Group type: COMPARATOR
Intervention: 60 mL water (placebo)
Number of subjects: 5
Study 17498850 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich supplementation
Number of subjects: 60
Study 17498850 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich supplementation + Nandrolone decanoate
Number of subjects: 60
Study 17498850 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 15017784 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium 40 micrograms
Number of subjects: 20
Study 15017784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15017784 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium
Number of subjects: 20
Study 12215193 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin therapy
Number of subjects: 0
Study 12215193 — intervention group
Group type: COMPARATOR
Intervention: Control (no early statin therapy)
Number of subjects: 0
Study 11477862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sini Decoction (SND)
Number of subjects: 40
Study 8570063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam (single dose)
Number of subjects: 129
Study 8570063 — intervention group
Group type: COMPARATOR
Intervention: Control (no cefotiam)
Number of subjects: 129
Study 2773842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular or oral administration of iron
Number of subjects: 191
Study 2773842 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 191
Study 790551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg daily
Number of subjects: 10
Study 790551 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 3 g daily
Number of subjects: 10
Study 30520201 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose peak > 30 minutes
Number of subjects: 93
Study 30520201 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour ≥ 155 mg/dL
Number of subjects: 93
Study 30520201 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic curve
Number of subjects: 93
Study 29392814 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person patient interview and follow-up telephone interview 3-5 months after discharge
Number of subjects: 1129
Study 29392814 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment from a key hospital worker
Number of subjects: 1129
Study 27059593 — intervention group
Group type: EXPERIMENTAL
Intervention: Respecting Choices program (intervention)
Number of subjects: 1360
Study 27059593 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 1360
Study 25030621 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care C-reactive protein test
Number of subjects: 62
Study 25030621 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in communication skills and use of an interactive patient booklet
Number of subjects: 62
Study 25030621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 62
Study 25030621 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced communication skills of GP
Number of subjects: 62
Study 25030621 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-patient test as an additional investigation
Number of subjects: 62
Study 22929469 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management consisting of intravenous fluids, prophylactic antibiotics, blood transfusions, anti-diarrheals, analgesics, and nutrition
Number of subjects: 48
Study 22929469 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control intervention mentioned)
Number of subjects: 48
Study 20334973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Risk Experimental (monthly urine screens, compliance checklists, individual and group motivational counseling)
Number of subjects: 42
Study 20334973 — intervention group
Group type: COMPARATOR
Intervention: High-Risk Control (standard control)
Number of subjects: 42
Study 20334973 — intervention group
Group type: COMPARATOR
Intervention: Low-Risk Control
Number of subjects: 42
Study 17666462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 5238
Study 17666462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238
Study 16320858 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) daily and twice daily 20 mg transdermal progesterone cream (PC)
Number of subjects: 26
Study 16320858 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine estrogen (CEE) daily and 2.5 mg medroxyprogesterone acetate (MPA)
Number of subjects: 26
Study 12193430 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at 6.0 IU/m2/day for at least two years
Number of subjects: 35
Study 12193430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 35
Study 9825314 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing with rate drop response function (11 patients)
Number of subjects: 20
Study 9825314 — intervention group
Group type: COMPARATOR
Intervention: DDI pacing with rate hysteresis (8 patients)
Number of subjects: 20
Study 8633181 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 60
Study 8633181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2698571 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil retard at a dosage of 75 mg b.i.d.
Number of subjects: 0
Study 62991 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 278
Study 62991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 62991 — intervention group
Group type: COMPARATOR
Intervention: No tablets at all
Number of subjects: 278
Study 31302489 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 week static calf stretching intervention
Number of subjects: 68
Study 31302489 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (control)
Number of subjects: 68
Study 26935479 — intervention group
Group type: EXPERIMENTAL
Intervention: pink-veneered zirconia abutments (test group; n = 10)
Number of subjects: 20
Study 26935479 — intervention group
Group type: COMPARATOR
Intervention: non-veneered white zirconia abutments (control group; n = 10)
Number of subjects: 20
Study 26652009 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative rectus sheath block (RSB)
Number of subjects: 64
Study 26652009 — intervention group
Group type: COMPARATOR
Intervention: Postoperative rectus sheath block (RSB)
Number of subjects: 64
Study 23787940 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Dance Revolution (supervised)
Number of subjects: 18
Study 23787940 — intervention group
Group type: COMPARATOR
Intervention: Handheld game (without supervision)
Number of subjects: 18
Study 21559803 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (n=37; average peak BAC=0.087 g/100 ml)
Number of subjects: 79
Study 21559803 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=42)
Number of subjects: 79
Study 18718886 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator enhanced multifaceted intervention
Number of subjects: 30
Study 18718886 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 30
Study 16374471 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl 5-aminolevulinate (MAL) cream at concentrations of 16-160 mg/g applied for 3 hours and 18 hours.
Number of subjects: 50
Study 16374471 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl 5-aminolevulinate (MAL) cream at concentrations of 16-160 mg/g applied for 18 hours.
Number of subjects: 50
Study 14984131 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster placement as an alternative to institutionalization
Number of subjects: 0
Study 14984131 — intervention group
Group type: COMPARATOR
Intervention: Institutionalization
Number of subjects: 0
Study 10886577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine
Number of subjects: 197
Study 10886577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 10886577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (in patients 10 years old or younger)
Number of subjects: 197
Study 10886577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients 10 years old or younger)
Number of subjects: 197
Study 8721273 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole a day orally for 4 days
Number of subjects: 10
Study 8721273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8134169 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 0.13 mumol/L (10 micrograms/L) Se
Number of subjects: 82
Study 8134169 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of solid foods
Number of subjects: 82
Study 8134169 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 0.26‐0.33 mumol/L (20‐25 micrograms/L) Se (suggested)
Number of subjects: 82
Study 8134169 — intervention group
Group type: EXPERIMENTAL
Intervention: Males vs. Females
Number of subjects: 82
Study 2891518 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH nasal spray
Number of subjects: 252
Study 2891518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 2891518 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-RH nasal spray (including subsequent open study and second course)
Number of subjects: 252
Study 2891518 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up period
Number of subjects: 252
Study 2891518 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective evaluation
Number of subjects: 252
Study 2891518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal evaluation
Number of subjects: 252
Study 2891518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment testicular position
Number of subjects: 252
Study 29903761 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 151
Study 25580428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 450
Study 25580428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 450
Study 25580428 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 450
Study 25580428 — intervention group
Group type: COMPARATOR
Intervention: All treatment options
Number of subjects: 450
Study 22213770 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 17
Study 22213770 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17
Study 20581420 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention
Number of subjects: 4603
Study 20581420 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control)
Number of subjects: 4603
Study 18616866 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (PS)
Number of subjects: 16
Study 18616866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16163628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 449
Study 16163628 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime with TMP-SMX
Number of subjects: 449
Study 12190760 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous cannula used for both intra‐operative and postoperative purposes
Number of subjects: 60
Study 12190760 — intervention group
Group type: COMPARATOR
Intervention: Two cannulae, one used intra‐operatively and the other postoperatively
Number of subjects: 60
Study 10589379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 0
Study 7850328 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant or concurrent single-agent cisplatin followed by local definitive treatment
Number of subjects: 804
Study 7850328 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin and doxorubicin)
Number of subjects: 804
Study 7850328 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 60 years
Number of subjects: 804
Study 2182103 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles treatment
Number of subjects: 0
Study 2182103 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study 2182103 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles treatment (subgroup of consistent wearers)
Number of subjects: 0
Study 2182103 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles treatment (subgroup of inconsistent wearers)
Number of subjects: 0
Study 377462 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision and skin grafting
Number of subjects: 222
Study 377462 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (scarlet red gauze dressing)
Number of subjects: 222
Study 31097519 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t‐PA)
Number of subjects: 0
Study 31097519 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human DNase
Number of subjects: 0
Study 31097519 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31097519 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA-DNase
Number of subjects: 0
Study 31097519 — intervention group
Group type: COMPARATOR
Intervention: placebo vs t‐PA-DNase
Number of subjects: 0
Study 28255812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training group (LIPRT, n=13, 15% maximal inspiratory workload, 0.5 kg peripheral muscle workload)
Number of subjects: 35
Study 28255812 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity training group (MIPRT, n=13, 30% maximal inspiratory workload, 50% of one maximum repetition of peripheral muscle workload)
Number of subjects: 35
Study 28255812 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (n=9)
Number of subjects: 35
Study 26047602 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Patients (SP)
Number of subjects: 57
Study 26047602 — intervention group
Group type: COMPARATOR
Intervention: High-Fidelity Simulators (HFS)
Number of subjects: 57
Study 22305437 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-SPACE
Number of subjects: 25
Study 22305437 — intervention group
Group type: COMPARATOR
Intervention: PC-MRI
Number of subjects: 25
Study 21310088 — intervention group
Group type: EXPERIMENTAL
Intervention: PURIAM110 dietary supplement
Number of subjects: 45
Study 21310088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19797148 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial lead placement
Number of subjects: 23
Study 19797148 — intervention group
Group type: COMPARATOR
Intervention: Transvenous CRT
Number of subjects: 23
Study 16915077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal manipulation
Number of subjects: 102
Study 16915077 — intervention group
Group type: COMPARATOR
Intervention: Low-power external physiotherapy
Number of subjects: 102
Study 14994556 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Attack Survival Kit delivered by firefighters
Number of subjects: 323
Study 14994556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 323
Study 11506108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration with 15 ml/kg crystalloid immediately before spinal anesthesia
Number of subjects: 48
Study 11506108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration with 15 ml/kg crystalloid starting with the spinal anesthetic injection
Number of subjects: 48
Study 11506108 — intervention group
Group type: COMPARATOR
Intervention: No prehydration (control)
Number of subjects: 48
Study 9143171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative sentinel lymph node mapping and biopsy using radiocolloid, handheld gamma probe, and vital blue dye.
Number of subjects: 0
Study 9143171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative sentinel lymph node mapping and biopsy.
Number of subjects: 0
Study 9143171 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification and removal of regional lymph nodes containing metastatic melanoma.
Number of subjects: 0
Study 8195987 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliation with someone awaiting the same threat
Number of subjects: 0
Study 8195987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal affiliation (facial glances)
Number of subjects: 0
Study 8195987 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliation effects on anxiety
Number of subjects: 0
Study 3066854 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (total dose of about 11 g/m2)
Number of subjects: 70
Study 3066854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 3066854 — intervention group
Group type: COMPARATOR
Intervention: Misonidazole and Placebo (combined)
Number of subjects: 70
Study 3066854 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 70
Study 29996798 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% duty cycle (DC) subthreshold laser treatment
Number of subjects: 20
Study 29996798 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% duty cycle (DC) subthreshold laser treatment
Number of subjects: 20
Study 29996798 — intervention group
Group type: COMPARATOR
Intervention: Continuous wave (CW) laser treatment
Number of subjects: 20
Study 28495809 — intervention group
Group type: COMPARATOR
Intervention: Intravenous potassium replacement (IVPR)
Number of subjects: 41
Study 28495809 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral potassium replacement (EPR)
Number of subjects: 41
Study 25608273 — intervention group
Group type: EXPERIMENTAL
Intervention: The Pink Women's Wellness Program (lifestyle intervention including clinical consultations and tailored health education)
Number of subjects: 55
Study 25608273 — intervention group
Group type: EXPERIMENTAL
Intervention: The Pink Women's Wellness Program
Number of subjects: 55
Study 25608273 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 55